Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1445483rdf:typepubmed:Citationlld:pubmed
pubmed-article:1445483lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C0047683lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C0033618lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C0036825lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C1511572lld:lifeskim
pubmed-article:1445483lifeskim:mentionsumls-concept:C1627340lld:lifeskim
pubmed-article:1445483pubmed:issue9lld:pubmed
pubmed-article:1445483pubmed:dateCreated1992-12-17lld:pubmed
pubmed-article:1445483pubmed:abstractTextThe serum concentrations of 3-keto-desogestrel have been measured in 43 women who took a low-dose oral contraceptive containing 30 micrograms ethinyl estradiol (CAS 57-63-6) together with 150 micrograms desogestrel (CAS 54024-22-5) for a period of 3 months. Basic pharmacokinetic parameters, like Cmax, tmax and AUC, as well as the serum protein binding of 3-keto-desogestrel were determined on days 1, 10 and 21 of the first and the third treatment cycle, respectively. During cycle one, Cmax, AUC(0-4h) and AUC(0-24h) values on day 1 were 1.9 +/- 0.7 ng/ml, 3.9 +/- 1.3 ng.ml-1.h and 12.4 +/- 5.7 ng.ml-1.h, respectively. These values increased to 4.7 +/- 2.0 ng/ml, 12.1 +/- 5.6 ng.ml-1.h and 47.3 +/- 26.0 ng.ml-1.h on day 21. Within cycle 3, a similar, although less steep increase was observed for these parameters and there was practically no difference in the values of corresponding parameters on day 21 of both cycles. Throughout treatment, there was a redistribution of 3-keto-desogestrel with respect to the binding proteins albumin and sex hormone binding globulin (SHBG). During cycle 1, the free fraction decreased from 1.8% on day 1 to 1.1% on day 21, and the SHBG-bound fraction increased at the same time from 40% to 62%, mainly at the expense of the albumin-bound fraction. During cycle 3, there were only minor changes as compared to cycle one. The observed changes in the serum protein binding were related to an increase in SHBG levels during the treatment period.lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:languageenglld:pubmed
pubmed-article:1445483pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:citationSubsetIMlld:pubmed
pubmed-article:1445483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1445483pubmed:statusMEDLINElld:pubmed
pubmed-article:1445483pubmed:monthSeplld:pubmed
pubmed-article:1445483pubmed:issn0004-4172lld:pubmed
pubmed-article:1445483pubmed:authorpubmed-author:BackD JDJlld:pubmed
pubmed-article:1445483pubmed:authorpubmed-author:KuhnzWWlld:pubmed
pubmed-article:1445483pubmed:authorpubmed-author:PowerJJlld:pubmed
pubmed-article:1445483pubmed:authorpubmed-author:JüttingGGlld:pubmed
pubmed-article:1445483pubmed:authorpubmed-author:al-YacoubGGlld:pubmed
pubmed-article:1445483pubmed:authorpubmed-author:OrmesherS ESElld:pubmed
pubmed-article:1445483pubmed:issnTypePrintlld:pubmed
pubmed-article:1445483pubmed:volume42lld:pubmed
pubmed-article:1445483pubmed:ownerNLMlld:pubmed
pubmed-article:1445483pubmed:authorsCompleteYlld:pubmed
pubmed-article:1445483pubmed:pagination1142-6lld:pubmed
pubmed-article:1445483pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:meshHeadingpubmed-meshheading:1445483-...lld:pubmed
pubmed-article:1445483pubmed:year1992lld:pubmed
pubmed-article:1445483pubmed:articleTitlePharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.lld:pubmed
pubmed-article:1445483pubmed:affiliationResearch Laboratory, Schering Aktiengesellschaft, Berlin/Bergkamen, Fed. Rep. of Germany.lld:pubmed
pubmed-article:1445483pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1445483pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1445483pubmed:publicationTypeRandomized Controlled Triallld:pubmed